RNA vaccine developer Moderna (MRNA) is sinking 9% after Goldman Sachs downgraded the shares to Neutral from Buy. Why Goldman ...

RNA vaccine developer Moderna (MRNA) is climbing nearly 5% in early trading today after it was awarded about $590 million by the U.S. government’s Department of Health and Human Services (HHS) on ...

US vaccines developer Moderna today announced that it has been awarded a tender for the supply of its mRNA COVID-19 vaccine ...

mRNA vaccine developer Moderna (MRNA) is climbing nearly 5% in early trading today after it was awarded about $590 million by the U.S. government’s Department of Health and Human Services (HHS ...

Vaxxas has announced that the CEPI, has approved the progression of a $7.2 million program to develop heat-stable, ...

In some good news for the US vaccines developer, whose stock has fallen 66% in the past 12 months, Moderna on Friday ...

Vaxxas and CEPI advance US$ 4.8 million programme for needle-free thermostable mRNA vaccines: Cambridge, Massachusetts Friday, January 24, 2025, 14:00 Hrs [IST] Vaxxas, a clinical ...

In this review of RNA therapies, we paint an overview of what’s going on in a field that is addressing a number of diseases.

In trials at University College London Hospitals (UCLH), an ASO is being used to target the mutated gene that results in the ...

Merck shares trade at a significant discount to peers. The company faces challenges, but there are reasons to be bullish.

WEST JEFFERSON, OHIO / ACCESS Newswire / January 30, 2025 / AmplifyBio, a leading preclinical CRO and CDMO played a pivotal ...

Considering that PD-1/L1 are some of the most lucrative drug treatments across the industry, this could be a major coup for any mRNA developer that manages to successfully co-develop such a treatment.